ArticleDrug design, development and therapy2025
YK-4-279 Induces Osteosarcoma Cell Cycle Arrest, DNA Damage Response, and Apoptosis by Regulating the MAPK Cascade.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: YK-4-279, a promising anticancer agent, has demonstrated therapeutic potential against various tumors. Osteosarcoma (OS), an aggressive bone cancer primarily affecting adolescents, lacks effective treatment options. Investigating YK-4-279's mechanisms in OS is critical for evaluating its clinical utility. Methods: Using in vitro models, we examined YK-4-279's effects on OS cell viability, proliferation, apoptosis, cell cycle progression, and DNA damage. We also assessed its impact on MAPK signaling pathway activation. To clarify the pathway's role, we combined YK-4-279 treatment with a P38 inhibitor. Results: YK-4-279 markedly suppressed OS cell viability and proliferation, triggered G2/M phase arrest, and enhanced apoptosis and DNA damage. Furthermore, it activated the MAPK pathway, elevating phosphorylation of ERK1/2, JNK, and P38 MAPK. Co-treatment with a P38 inhibitor partially reversed these effects, confirming MAPK's involvement in YK-4-279's antitumor action. Conclusion: YK-4-279 inhibits OS cell growth, induces DNA damage and cell cycle arrest, and promotes apoptosis via MAPK pathway activation. These findings highlight its strong therapeutic potential for OS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.